Tactile Systems Technology, Inc. (TCMD) - Stock Analysis
Last updated: Jun 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q4 beat with 21% revenue growth, margin expansion, deleveraging (term loan repaid), and a buyback plus positive clinical data for Flexitouch have produced a sharp breakout (~10% over 21 days, 15% above the 21-day SMA); near-term upside is supported by strong fundamentals and follow-through on payer/volume metrics.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Expense pressure ⢠Profitability risk TCMD has a strong balance sheet and high gross margins, but the latest quarter showed profitability and cash flow deteriorating due to operating expense pressure, making execution the key risk.
Price Behavior
Key Price Behavior Insights: ⢠Base defense ⢠Overhead resistance ⢠No breakout Support Level: $23.0-$23.5 Resistance Level: $25.6-$26.0 TCMD has improved over the last month after rebounding from the mid-May low and holding $23.0-$23.5 support, but it remains below $25.6-$26.0 resistance and has not confirmed a breakout yet.
Sentiment & News
Key News Insights: ⢠AffloVest launch ⢠Adherence focus ⢠Investor outreach Tactile Medical is expanding investor awareness while fully launching its next-generation AffloVest to strengthen its airway-clearance portfolio and support patient adherence.
AI Summary
TCMD is shifting from a clean high-margin medtech to a proof-of-execution story, where the stock's upside now depends on AffloVest-led revenue momentum converting into sustained operating leverage and positive cash flow, because recent growth has not yet overcome rising expenses.
Description
Tactile Systems Technology, Inc. is a U.S.-based medical device company that produces and markets noninvasive therapies for chronic conditions. Its product portfolio includes pneumatic compression systems for lymphedema and other venous disorders and a portable chest wall oscillation device for managing retained pulmonary secretions. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 19 | Feb 26 | TCMD | Tactile Systems Technology, Inc. | Q4 beat with 21% revenue growth, margin expansion, deleveraging (term loan repaid), and a buyback plus positive clinical data for Flexitouch have produced a sharp breakout (~10% over 21 days, 15% above the 21-day SMA); near-term upside is supported by strong fundamentals and follow-through on payer/volume metrics. | Closed | +5.9% |